Global brokerage firm UBS has initiated coverage on several pharma stocks, highlighting potential upsides and challenges within the sector. The report points to weakening trends in both India and the US, with underappreciated growth slowdowns in these markets. UBS has provided a mixed outlook, issuing both ‘Buy’ and ‘Sell’ ratings on a range of pharmaceutical stocks.Here is a list of 6 pharma stocks on which UBS initiated coverage:
Titagarh Rail Systems Q4 results: Net profit declines 18% YoY, revenue down by 4%
Titagarh Rail Systems reported a consolidated net profit of Rs 64.45 crore for Q4FY25, an 18.6% YoY decrease, with revenue from operations declining by 4.45%
May 31, 2025